Use of prothrombin complex concentrates in anticoagulation.
van Veen
Suzanne Q
SQ
Strengers
Paul F W
PF
D000925:Anticoagulants / Q000009:adverse effects / Q000037:antagonists & inhibitors*; D001779:Blood Coagulation Factors / Q000737:chemistry / Q000627:therapeutic use*; D005164:Factor IX / Q000008:administration & dosage / Q000627:therapeutic use; D005167:Factor VII / Q000008:administration & dosage / Q000627:therapeutic use; D015942:Factor VIIa / Q000008:administration & dosage / Q000627:therapeutic use; D005170:Factor X / Q000008:administration & dosage / Q000627:therapeutic use; D006474:Hemorrhagic Disorders / Q000139:chemically induced / Q000188:drug therapy*; D006801:Humans; D011516:Prothrombin / Q000008:administration & dosage / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D014812:Vitamin K / Q000037:antagonists & inhibitors
D000925:Anticoagulants; D001779:Blood Coagulation Factors; D011994:Recombinant Proteins; D014812:Vitamin K; C025667:prothrombin complex concentrates; D005167:Factor VII; D011516:Prothrombin; D005164:Factor IX; D005170:Factor X; C103587:recombinant FVIIa; D015942:Factor VIIa